FORMULATION AND IN-VITRO EVALUATION OF EFAVIRENZ LIQUISOLID COMPACTS
Objective: The present research is aimed to enhance the dissolution rate of Efavirenz using liquisolid compact technology.
Methods: About 16 different formulations were developed using factorial design with carriers (Neusilin and Fugicalin), binder (PVP K-30) and vehicle (polyethylene glycol 300) as independent variables and aerosil 200 is used as coating material. The In-vitro drug release from the LSC has used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials.
Results: A 23 factorial design is used and developed LSC using Neusilin (LSC-N1 to LSC-N8) and Fugicalin (LSC-F1 to LSC-F8). The physicochemical evaluation of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content uniformity. The In-vitro drug release from these LSC was evaluated in 0.1 N HCl and the optimized formulation (LSC-N8) was compared with pure drug (capsule) and physical mixture (tablet). The release studies proved that the liquisolid tablets results in higher release profile than pure drug and physical mixture due to increase in surface and wetting properties of the drug.
Conclusion: LSC technique confirmed the enhanced dissolution rate of Efavirenz, which in turn helps in improving bioavailability.
2. Charman SA, Charman WN. Oral modified release delivery systems-Modified Release Drug Delivery Technology; New York: 2003. p. 1-9.
3. Christian L, Jennifer D. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
4. Darwish AM, El-Kamel AH. Dissolution enhancement of glibenclamide using liquisolid tablet technology. Acta Pharm 2001;51:173-81.
5. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69:993-1003.
6. Jagan Mohan Vatyam, Ch S Vijaya Vani, V Umamaheshwara Rao. Enhancement of solubility and dissolution rate of efavirenz using liquisolid compact technique. Int J Pharm 2014;4:150-6.
7. Javadzadih Y, Stahi MR, Asnaashari S, Nokhodchi A. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties. Acta Pharm 2007;57:99â€“109.
8. Kang MJ, Jung SY, Song WH, Park JS, Choi SU, Oh KT, et al. Immediate release of efavirenz from FujicalinÂ®-based fast-dissolving self-emulsifying tablets. Drug Dev Ind Pharm 2011;31:1298-305.
9. Kavitha K, Kotha NS, Lova Raju, NS Ganesh, B Ramesh. Effect of dissolution rate by liquisolid compact approach: an overview. Scholar Res Library 2011;3:71-83.
10. Matsunaga H, Eguchi T, Nishijima K, Enomoto T, Sasaoki K, Nakamura N. Solid state characterization of candesartan cilexetil (TCV-116): Crystal structure and molecular mobility. Chem Pharm Bull 1999;47:182-6.
11. Naveen C, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012;2:502-8.
12. Neelam Sreedhar, Sonu Bhatia. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003;4:E33.
13. Nokhodchi A. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Sci 2010;12:18-25.
14. Pratik Kumar A. Commercial telmisartan tablets: a comparative evaluation with innovator brand micardis pratik Kumar A. Int J Pharm Sci Res 2010;1:282-92.
15. Rajesh K, Raja Lakshmi R, Uma Maheswari J, Ashok Kumar C. Liquisolid technique a novel approach to enhance solubility and bioavailability. Int J Biopharm 2011;2:8-13.
16. Sanjeev Raghavendra Gubbi, Ravindra Jarag. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian J Pharm Sci 2010;5:50-60.
17. Sharma D. Solubility enhancement-eminent role in poorly soluble drugs. Res J Pharm Technol 2009;2:220-4.
18. Spireas S, Bolton M. Liquisolid systems and methods of preparing same. U. S. Patent; 1999. p. 968, 550.
19. Tiong N, Elkordy AA. Effects of liquisolid formulations on the dissolution of naproxen. Eur J Pharm Biopharm 2009;73:373-84.
20. Vijay kumar Nagabandi, Ramarao Tadikonda, Jayaveera KN. Formulation development and evaluation of liquisolid system to improve the dissolution rate of Ketoprofen. Int J Biomed Res 2011;2:530-41.
21. Vijay N, Ramarao T, Jaya Veera K. Liquisolid compacts a novel approach to enhance bioavailability of poorly soluble drugs. Int J Pharm Biol Sci 2011;1:89-102.
22. Wen X, Tan F, Jing Z, Liu Z. Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 2004;34:517-23.